GCP
ZNTL icon

GSA Capital Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

GSA Capital Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.45M Sell
620,407
-549,166
-47% -$1.42M 0.09% 297
2025
Q4 		$1.58M Buy
1,169,573
+91,917
+9% +$134K 0.14% 162
2025
Q3 		$1.63M Sell
1,077,656
-55,719
-5% -$83.5K 0.14% 147
2025
Q2 		$1.31M Buy
1,133,375
+591,400
+109% +$780K 0.09% 296
2025
Q1 		$862K Buy
541,975
+397,805
+276% +$858K 0.08% 438
2024
Q4 		$437K Sell
144,170
-464,415
-76% -$1.52M 0.03% 985
2024
Q3 		$2.24M Buy
608,585
+353,384
+138% +$1.28M 0.17% 91
2024
Q2 		$1.04M Buy
255,201
+244,599
+2,307% +$2.73M 0.07% 475
2024
Q1 		$167K Buy
+10,602
New +$146K 0.01% 1434
2023
Q4 		– Sell
-24,344
Closed -$488K – 2000
2023
Q3 		$488K Buy
+24,344
New +$618K 0.04% 818
2022
Q2 		– Sell
-12,979
Closed -$599K – 1867
2022
Q1 		$599K Sell
12,979
-13,885
-52% -$749K 0.08% 423
2021
Q4 		$2.26M Buy
+26,864
New +$2.08M 0.28% 13

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

GSA Capital Partners's ZNTL Position: Q1 2026 in Review

GSA Capital Partners reduced its Zentalis Pharmaceuticals (ZNTL) stake by 47% in Q1 2026, selling an estimated $1.42M and leaving 620,407 shares worth $1.45M. The position accounts for 0.09% of the portfolio, ranked #297.

GSA Capital Partners first reported a position in ZNTL in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.26M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • GSA Capital Partners held 620,407 shares of Zentalis Pharmaceuticals worth $1.45M as of Q1 2026.
  • GSA Capital Partners sold 549,166 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.42M.
  • Zentalis Pharmaceuticals made up 0.09% of GSA Capital Partners's portfolio in Q1 2026, its #297 holding.
  • GSA Capital Partners first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • GSA Capital Partners's Zentalis Pharmaceuticals position peaked at $2.26M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.